# BiOptix Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioptix-diagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Boulder, US
- Website: www.bioptixinc.com
- Total disclosed funding: $23M
- Latest round: Series C (May 13, 2016)
- Investors on record: 4

## About

BiOptix Diagnostics Inc. specializes in developing and providing innovative reagents and assays for biomedical research and clinical applications, focusing on cancer research and therapeutic development.BiOptix Diagnostics Inc. was founded in 2008 and is headquartered in Boulder, US. The company is known for its specialization in high-quality reagents and assays. In September 2016, BiOptix was acquired by Venaxis, Inc., with the terms of the sale undisclosed. The company has successfully completed a total of 8 deals and raised USD 0.80 mn in its latest funding round, Series C, led by Boulder Ventures, bringing its current valuation to USD 15.024 mn.BiOptix Reagents and Assays specializes in developing high-quality reagents and assays for biomedical research and clinical applications. Their core products include cell lines such as NCI-H226 for lung cancer research and PaTu 8988t for pancreatic cancer studies, along with recombinant proteins like the Sonic Hedgehog (Shh) protein. These products are utilized by a diverse clientele, including academic institutions and biotech companies across North America, Europe, and Asia, contributing to advancements in cancer research and targeted therapies.BiOptix Reagents and Assays generates revenue through direct sales of its specialized reagents and assays to various research institutions and pharmaceutical companies. Transactions are primarily conducted on a B2B basis, with flexible pricing plans including bulk purchases for high-volume clients. Key products such as the NCI-H226 and PaTu 8988t cell lines play a crucial role in the company’s revenue structure, catering to high-demand research applications in oncology.Looking ahead, BiOptix Diagnostics Inc. is focused on expanding its product line and entering new markets. The company has plans to launch new products designed for specific cancer research applications, which they expect to introduce by late 2017. Furthermore, BiOptix aims to penetrate additional markets in Europe and Asia by 2018. The funding from the Series C round will support these product developments and market expansions, following their acquisition by Venaxis, Inc. in September 2016.

## Funding rounds

- Series C, May 13, 2016, $0.8M — Boulder Ventures
- Series C, Feb 26, 2015, $1.5M — Boulder Ventures
- Series C, Aug 13, 2014, $2M — Boulder Ventures, RUSNANO Management Company, Remeditex Ventures
- Series C, Mar 13, 2013, $6.2M — Boulder Ventures
- Series B, Mar 24, 2011, $9M — Boulder Ventures, Peierls Foundation, RUSNANO Management Company
- Series A, Mar 11, 2009, $3M — Boulder Ventures

## Investors

- Boulder Ventures (https://capitalatlas.ai/funds/boulder-ventures) — Series A, Series B, Series C
- Peierls Foundation — Series B
- RUSNANO Management Company — Series B, Series C
- Remeditex Ventures (https://capitalatlas.ai/funds/remeditex-ventures) — Series C